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OBJECTIVE: Hospitalization and inpatient charge comparisons
for bipolar and manic patients receiving atypical and conven-
tional antipsychotics. METHODS: Analysis of a claims database
(1999–2003) representing 50 million US insured patients 
identiﬁed 12,835 treatment episodes of monotherapy for bipolar
and manic disorders with atypicals (risperidone, olanzapine, 
quetiapine, ziprasidone) and conventionals (haloperidol, 
perphenazine, thioridazine, thiothixene). Hazard ratios (HR) for
hospitalization risks were estimated with Cox regression adjust-
ing for patient characteristics. Inpatient charges were based on
these estimates and estimated hospital stays. RESULTS: Risperi-
done and olanzapine had signiﬁcantly (P < 0.05) higher risks of
hospitalization than quetiapine (HR 1.185 and 1.187, respec-
tively) and trended (P < 0.10) toward higher risks than ziprasi-
done (HR 1.443 and 1.447, respectively), translating into higher
inpatient charges of $194–$389 per patient per year. On com-
paring the atypicals in manic rapid cyclers (a high hospitaliza-
tion subgroup), risperidone had a signiﬁcantly (P < 0.05) higher
risk of hospitalization than olanzapine (HR = 3.309) and olan-
zapine trended (P < 0.10) toward longer stays than quetiapine
(7.56 days longer), both translating into higher inpatient charges.
CONCLUSION: In treating bipolar and manic disorders, risperi-
done and olanzapine may have higher risks of hospitalization
than quetiapine. In treating manic rapid cyclers, olanzapine may
have a lower risk of hospitalization than risperidone, but longer
stays than quetiapine.
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OBJECTIVES: To determine the prevalence of patients with
bipolar disorder (BD) and compare their annual health care costs
to patients with other mental health disorders, in a large United
States managed care organization. METHODS: This was a ret-
rospective claims analysis of approximately 1.4 million com-
mercial health plan members with mental health beneﬁts. Adults
with a primary or secondary diagnosis of a mental health disor-
der in 2002 were identiﬁed and the prevalence of BD calculated.
Those continuously enrolled throughout 2003 (follow-up
period) were stratiﬁed to one of two cohorts: “BD” (Bipolar 
Disorder) or “OMHD” (Other Mental Health Disorder). Patient
demographics, pharmacological treatments, and health care
charges were compared between cohorts, adjusting for potential
confounding factors of age, gender, and comorbidity. RESULTS:
During 2002, there were 6581 patients (mean age 40.3 years;
65.7% female) with BD, yielding an overall prevalence rate of
4.68 per 1000 members. Among the 64,434 continuously
enrolled mental disorder patients in 2003, 3,043 (4.7%) were
classiﬁed as “BD” and 61,391 (95.3%) were classiﬁed as
“OMHD”. Patients in the “BD” group were younger (41.7 vs.
43.0 years; p < 0.0001) with higher Charlson comorbidity index
(0.56 vs. 0.47; p < 0.0001) compared to the “OMHD” group.
Less than half (38.3%) of “BD” patients received a mood sta-
bilizer (lithium, valproate, or carbamazepine) and 20.0%
received no psychotropic medication. Adjusted pharmacy,
medical, and total health care charges were higher in the “BD”
group compared to “OMHD”: $2641 vs. $1071, $13,419 vs.
$8422, and $16,059 vs. $9493 respectively (p < 0.0001 for all
three comparisons). CONCLUSIONS: Compared to the national
prevalence rate of 1%, BD may be under-diagnosed, and phar-
macologic therapy underutilized within managed care. Patients
with BD incurred greater health care charges compared to other
mental health disorders. Efforts aimed at improving diagnosis
and treatment of BD may optimize care and cost of managing
this patient population.
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OBJECTIVES: Existing research offers little empirical evidence
to support national practice guidelines about antidepressant use
in patients with bipolar disorder. This study assessed the clinical
and economic impact of second-generation antidepressant use
for bipolar depressed adult patients. METHODS: Bipolar disor-
der subjects were identiﬁed with a new depressive episode in a
national managed-care plan between January, 1998 and Decem-
ber, 2002. In total, 3737 patients were deﬁned with the index of
interested medication initiation and at least three-months pre-
index and 12-month post-index continuous enrollments. Logit
model with a difference-in-difference approach was employed to
identify the relationship between treatment types (antidepressant
monotherapy, mood stabilizer monotherapy, and antidepressant-
mood stabilizer combination therapy) and the probability of
mania-related visits. In addition, negative binomial model and
log-transformed OLS model were used to predict number of
depression-related visits and health care costs respectively.
RESULTS: Probability of mania-related visits increased signiﬁ-
cantly from pre-index to post-index period with odds ratio 2.40
(95% CI: 1.52–3.79) for antidepressant monotherapy compared
to mood stabilizer monotherapy, controlling for time ﬁxed-effect,
demographics, clinical-related and health-related variables.
However no signiﬁcant difference was identiﬁed between com-
bination therapy and mood stabilizer monotherapy. Patients 
with antidepressant monotherapy and combination therapy had
signiﬁcantly lower incidence rate ratios of 0.68 (95% CI:
0.56–0.82) and 0.65 (95% CI: 0.52–0.81) respectively for
depression-related visits, but signiﬁcantly higher bipolar-related
costs (232% and 72% respectively) compared to patients with
mood stabilizer monotherapy. CONCLUSIONS: This study adds
to the literature of bipolar depression treatment by providing
empirical evidence at the national level to support the current
practice guidelines. Second-generation antidepressant monother-
apy indicated a risk of induced manic-switching, which can be
costly in terms of overall health care resources. Since the safety
and efﬁcacy of antidepressants in bipolar disorder have not been
ﬁrmly established, medical practitioners and policy makers
should take precautions regarding the appropriate use of new
antidepressants.
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OBJECTIVES: To assess the clinical outcomes of modern
second-generation antidepressant medication use in bipolar dis-
order, with a focus on the risk of induced manic-switching for
adult patients with bipolar depression. METHODS: Bipolar dis-
order subjects were identiﬁed with a new depressive episode in
a national managed care plan between January, 1998 and
December, 2002. A case-control study design was applied for
which cases and controls were deﬁned by whether having mania-
related visits in the 12-months continuous enrollment after
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episode initiation. The date of ﬁrst mania-related visit after
depression was the index date of manic-switching for cases and
a random date was assigned for controls. Based on the pharmacy
records, 2050 patients were established having treatment of anti-
depressant monotherapy, mood stabilizer monotherapy, or anti-
depressant-mood stabilizer combination therapy within 30 days
prior to the index date. A logistic regression with difference-
in-difference approach was employed to predict the probabilities
of having manic-switching by different types of treatment.
RESULTS: Patients with antidepressant monotherapy and anti-
depressant-mood stabilizer combination therapy were 31% (n =
87) and 29% (n = 82) in the case group and 43% (n = 768) and
27% (n = 481) in the control group. Using logistic regression to
adjust for patient demographics, clinical-related and health-
related variables, the odds ratios for having manic-switching 
in relation to antidepressant monotherapy and antidepressant-
mood stabilizer combination therapy were 2.71 (95% CI:
1.32–5.56; p < 0.01) and 1.51 (95% CI: 0.81–2.81; p = 0.20)
respectively, compared to mood stabilizer monotherapy. CON-
CLUSIONS: This study further validates the national practice
guidelines for bipolar disorder with a case-control study design,
which does not have the study limitations of typical intent-to-
treat approach. Similar results were identiﬁed, indicating a risk
of induced manic-switching by antidepressant monotherapy yet
not by antidepressant-mood stabilizer combination therapy with
second-generation antidepressants.
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OBJECTIVES: Newer atypical antipsychotic medications were
recently approved by the FDA for treatment of bipolar disorder.
Although cost-effective pharmacotherapy can signiﬁcantly lower
total medical utilization and costs, economic evaluation studies
of pharmacotherapy in bipolar disorder are limited, particularly
for aytypical antipsychotics. This report reviews and identiﬁes
gaps in the current literature regarding impact of pharma-
cotherapy on health care utilization and costs among bipolar
patients. METHODS: A literature search was conducted using
Medline, CINHAL, International Pharmaceutical Abstracts and
Cochrane Collaborative databases for studies published between
January, 1990 and November, 2004. Abstracts presented at
American Psychiatric Association, National Institute of Mental
Health, and International Society of Pharmacoeconomics and
Outcomes Research were also examined. Articles were reviewed
to determine relevance to health care cost and utilization out-
comes associated with bipolar disorder pharmacotherapy.
RESULTS: The systematic search identiﬁed two randomized con-
trolled trials, two studies using administrative claims databases,
two studies using retrospective chart reviews and one study using
decision-modeling. Two studies reported that atypical antipsy-
chotic olanzapine reduced hospitalizations as compared to
placebo and typical antipsychotics. There were no studies com-
paring outcomes between different atypical antipyschotics for
bipolar disorder. Studies evaluating multiple endpoints between
ﬁrst-line pharmacotherapy and combinations of adjunct phar-
macotherapy were also lacking. Divalproex exhibited better cost
and utilization outcomes as compared to other pharmacothera-
pies (olanzapine, lithium and carbamazepine). Reduction in total
direct costs of bipolar disorder with use of any pharmacother-
apy was mostly attributable to reduced hospital stay. CON-
CLUSIONS: It is difﬁcult to compare utilization and cost
outcomes between pharmacotherapies due to the lack of head-
to-head studies, differences in research design and population
characteristics, and lack of cost-effectiveness studies determining
relative value of each pharmacotherapy for bipolar disorder.
Comprehensive evaluations of the impact of therapy on differ-
entiated economic endpoints relevant to practice policies (drug
costs, outpatient costs, hospitalizations, emergency room visits)
are needed.
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COMPARISON OF OLS AND PANEL ESTIMATION
Perkins PI, Johnson ED, Dickson WM
University of South Carolina, Columbia, SC, USA
OBJECTIVES: To evaluate the effect of the July, 2001 prescrip-
tion limit policy change in the South Carolina Medicaid program
on the utilization of health care services and their related costs
for adult Medicaid recipients diagnosed with schizophrenia 
or bipolar disorder. METHODS: A retrospective cohort study
design, identifying subjects with schizophrenia and bipolar dis-
order compared their utilization of health care services and asso-
ciated costs 18-months before and after the policy change (July,
2001). Eligible patients were age 21 or older, had a qualifying
diagnosis on a hospital or ambulatory claim, and a prescription
medication for their diagnosis within 90 days (+/-) of their 1998
or 1999 enrollment date. Total health care cost and service uti-
lization were estimated by ordinary least squares regres-
sion models and the results contrasted with panel regression
methods due to the short time series. Predictor variables were
demographics, inpatient hospitalization, and comorbidities.
RESULTS: OLS and panel estimation show an increase in total
cost and the number of ambulatory, hospital, prescription, and
nursing home claims after the policy change. Panel estimation
shows a positive monthly trend in the post period for all claims.
CONCLUSIONS: The policy change resulting in an increase in
average monthly patient prescription cost is associated with
increases in total cost of care and overall health care utilizations.
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OBJECTIVES: When conducting analysis using observational
data, there is often selection bias for which we must account for
in order to adjust for pre-treatment differences between groups
in baseline characteristics. This study compared the ordinary
regression, propensity score weighting, propensity score match-
ing, and difference-in-difference (DD) methods while addressing
the impact of second-generation antidepressant use in adult
patients with bipolar disorder. METHODS: A logit model was
developed, as an ordinary approach, to predict the probability
of having post-index mania-related visits from treatment types,
controlling for individual demographics, clinical-related vari-
ables, health-related variables, and pre-index mania-related
visits, serving as the baseline disease severity of bipolar disorder.
The propensity score method added more bipolar severity vari-
ables to predict the propensity to be with one treatment type,
without the problem of over-parameterization in the outcome
model. Both weighting and greedy matching approaches were
applied after the ﬁrst-stage propensity score model achieved the
covariates balancing. For DD model, a logistic regression was
